Shots:

• The approval is based on the pivotal AURORA P-III study and AURA-LV P-II study involves assessing of Lupkynis + SoC in 533 patients to treat adult patients with LN
• The study demonstrated significantly improved renal response rates vs SoC- improved response rates in all parameters across immunologically-active classes- 50 % reduction in UPCR twice as fast as SoC- complete renal response @24 wks vs SoC @1year
• Lupkynis is the 1^st FDA-approved oral therapy for LN and is now commercially available in the US

 ­ Ref: Businesswire | Image: Aurinia Pharmaceuticals